Screener
Taysha Gene Therapies, Inc. TSHA Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344610
| Line item | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|
| Net loss | $(89,049) | $(48,411) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 586 | 560 |
| Stock-based compensation | 11,357 | 6,484 |
| Non-cash net gain on lease termination | (5,108) | — |
| Change in fair value of warrant liability | — | 171 |
| Non-cash change in fair value of term loan | 115 | 441 |
| Non-cash lease expense | 556 | 647 |
Item 1. Financial Statements.
FAQ
- What is Taysha Gene Therapies, Inc.'s stock-based comp?
- Taysha Gene Therapies, Inc. (TSHA) reported stock-based comp of $5.81M in Q2 2026.
- How has Taysha Gene Therapies, Inc.'s stock-based comp changed year-over-year?
- Taysha Gene Therapies, Inc.'s stock-based comp increased by 82.1% year-over-year, from $3.19M to $5.81M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s stock-based comp has grown at a -7.5% compound annual growth rate (CAGR), from $18.18M to $13.3M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Taysha Gene Therapies, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude